News Center
Details
Yichang Renfu Pharmaceutical’s Celecoxib Capsules Have Been Approved for Market Launch.
Release time:
2025-02-05 08:35
Source:
Recently, Yichang Renfu Pharmaceutical received the “Drug Registration Certificate” for celecoxib capsules, approved and issued by the National Medical Products Administration. This product was approved for marketing under Category 4 of chemical drugs and is deemed to have passed the consistency evaluation.
Celecoxib is primarily indicated for the relief of symptoms and signs associated with osteoarthritis, adult rheumatoid arthritis, and ankylosing spondylitis, as well as for the treatment of acute pain in adults. The original branded drug was approved for marketing in the United States in 1998. It successfully addressed the longstanding challenge of gastrointestinal damage associated with traditional nonsteroidal anti-inflammatory analgesics and has been hailed as a “landmark breakthrough.”
The launch of Yichang Renfu Pharmaceutical’s Celecoxib Capsules further enriches the company’s product portfolio, strengthens its competitiveness in the domestic market, and boosts its overall market share. Going forward, the company will actively promote the commercialization and sales of this product, bringing more options to patients.
Trending News
Corporate culture
Make drug launches safer and faster, and ensure the tree of life remains evergreen.
Learn moreContact Us
Business customer service
-
Telephone：:+86-027-86506632
Human Resources Department
Address: No.98 shendun 2nd Road, Donghu New Technology Development Zone, Wuhan
Official wechat
Copyright: Wuhan humanwell likang pharmaceutical co.,ltd